

| | | | |
|-----------------------------------------------------------------------------------------------------------------------|--|--------------------------------|-----------------------|
| MODIFIED FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (REV. 6-89) PATENT AND TRADEMARK OFFICE | | ATTY DOCKET NO.: NMT-8440 | SERIAL No. 10/716,929 |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use several sheets if necessary)</i> | | APPLICANT(S): Rekha Bansal | |
| | | FILING DATE: November 19, 2003 | GROUP: 1644 |

NON-PATENT LITERATURE DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

| | |
|---|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| A | Arnstead et al., "Removal of activated complement from shed blood: comparison of high-and low-dilutional haemofiltration". <i>Acta Anaesthesiol Scand.</i> 1998 Aug;42(7):811-5. |
| B | Buono et al., "Influence of C3 Deficiency on Atherosclerosis". <i>Circulation</i> 2002;105;3025-3031 |
| C | Carter et al., "Humanization of an anti-p185 ^{HER2} antibody for human cancer therapy", <i>Proc. Natl. Acad. Sci USA</i> , Vol 89, pp 4285-4289, May 1992 |
| D | Chenoweth, D.E., "Complement activation during cardiopulmonary bypass: evidence for generation of C3a and C5a anaphylatoxins. <i>N Engl J Med</i> , 1981. 304(9): p. 497-503. |
| L | Clackson et al., "Making antibody fragments using phage display libraries", <i>Nature</i> 352, 624-628 August 15, 1991 |
| F | Clardy, C.W., "Complement activation by whole endotoxin is blocked by a monoclonal antibody to factor B." <i>Infect Immun</i> , 1994. 62(10): pp 4549-55 |
| G | Dahl et al., "MASP-3 and its association with distinct complexes of the Mannan-Binding Lectin Complement Activation Pathway", <i>Immunity</i> , Vol. 15, 127-135, July 2001 |
| H | Dang, "Relationship between developmental stenosis of cervical spinal canal and spinal cord injury", <i>Zhonghua Wai Ke Za Zhi</i> , 1992 Nov;29(12):724-6, 796 |
| H | Dreyer, WJ, et al. "Neutrophil accumulation in ischemic canine myocardium. Insights into time course distribution, and mechanism of localization during early reperfusion". <i>Circulation</i> 1991; 84;400-411 |
| J | Eaton S., et al. "Assay for Plasma Complement Activation by x-ray contrast media". <i>Invest Radiol</i> , 1990. 25(7):p. 789-92. |
| P | Entman, Mark L., et al. "Neutrophil induced oxidative injury of cardiac myocytes", <i>J. Clin. Invest.</i> Vol 90, 1992, p. 1335-1345 |
| L | Espinoza, Diego G. et al., "Macrophage Depletion Diminishes Lesion Size and Severity in Experimental Choroidal Neovascularization", <i>Invest Ophthalmol Vis Sci</i> . 2003;44:3586-3592 |
| M | Frederick, G.N., L. Truedsson, and A.G. Sjoholm, "New procedure for the detection of complement deficiency by ELISA. Analysis of activation pathways and circumvention of rheumatoid factor influence". <i>J Immunol Methods</i> , 1993: 166(2): p. 263-70 |
| N | Gyoten, M., <i>Activation of the complement system and cytokine production by radiographic contrast media in vascular endothelial cell in vitro</i> , <i>Nippon Igaki Hoshasen Gakkai Zasshi</i> . 1998 Dec;58(14):811-5. |
| O | Halstensen TS, Brandtzaeg P., <i>Local Complement activation in inflammatory bowel disease</i> , <i>Immunol Res</i> . 1991; 10(3-4): 485-92. |
| P | Halstensen TS, et al., <i>Epithelial deposition of immunoglobulin G1 and activated complement (C3b and terminal complement complex) in ulcerative colitis</i> , <i>Gastroenterology</i> . 1990 May;98(5 pt 1):1264-71. |
| Q | Hikawa, Maoshi, et al., <i>Method for production of neuronal hybridoma using emetine and actinomycin D</i> , <i>Brain Research Protocols</i> 1 (1997) 224-226. |

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP §609;
Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the patent applicants' attorney.

| | | | |
|--------------------------------------------------------------------------------------------------|--|--------------------------------|--------------------------|
| MODIFIED FORM PTO-1449 (REV. 6-89) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE | | ATTY DOCKET NO.: NMT-8440 | SERIAL NO. 10/716,929 |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use several sheets if necessary)</i> | | APPLICANT(S): Rekha Bansal | |
| | | FILING DATE: November 19, 2003 | GROUP: 1644 |

NON-PATENT LITERATURE DOCUMENTS (*Including Author, Title, Date, Pertinent Pages, Etc.*)

| | |
|---|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| A | Horiuchi, T., et al., <i>Human complement factor B: cDNA cloning, nucleotide sequencing, phenotypic conversion by site-directed mutagenesis and expression</i> . Mol Immunol. 1993. 30 (17): p. 1587-92. |
| B | Hourcade, D.E., L.M. Wagner, and T.J. Oglesby, <i>Analysis of the short consensus repeats of human complement factor B by site-directed mutagenesis</i> . J Biol Chem, 1995. 270 (34): p. 19716-22. |
| C | Ikeda, Ken et al., <i>Serum lectin with known structure activates complement through the classical pathway</i> , Journal of Biological Chemistry. 1987 262(16): p. 7451-7454 |
| D | Isaacs, J.D., et al., <i>Therapy with monoclonal antibodies. An in vivo model for the assessment of therapeutic potential</i> . J Immunol, 1992. 148 (10): p. 3062-71. |
| E | Jones HM, et al., <i>Cardiopulmonary bypass and complement activation. Involvement of classical and alternative pathways</i> ., Anaesthesia. 1982 Jun;37(6):629-33. |
| F | Jones, Peter T. et al., <i>Replacing the complementarity-determining regions in a human antibody with those from a mouse</i> , Nature 321, 522-525, May 29, 1986 |
| G | Kawana S. et al., <i>Membrane attack complex of complement in Henoch-Schönlein purpura skin and nephritis</i> , Arch Dermatol Res. 1990;282(3):187-7. |
| H | Kilpatrick, David C., <i>Mannan-Binding lectin: clinical significance and applications</i> , Biochimica et Biophysica Acta 1572 (2002) 401-413. |
| L | Kitano A., et al., <i>New treatment of ulcerative colitis with k-76</i> , Dis Colon Rectum. 1992 Jun;35(6):560-7. |
| J | Kolios G. et al., <i>Mediators of inflammation: production and implication in inflammatory bowel disease</i> . Hepatogastroenterology. 1998 Sept-Oct;45(23):1601-9. |
| P | Lonberg Nils, et al., <i>Antigen-specific human antibodies from mice comprising four distinct genetic modifications</i> , Nature 368, 856-859: April 28, 1994. |
| L | Marks, J.D. et al., <i>By-passing immunization. Human antibodies from v-gene libraries displayed on phage</i> , J Mol Biol. 1991 Dec5;222(3):581-597. |
| M | Moore, F.D., Jr., et al., <i>The effects of complement activation during cardiopulmonary bypass. Attenuation by hypothermia, heparin, and hemodilution</i> . Ann Surg, 1988. 208 (1): p. 95-103. |
| N | Morgan BP et al., <i>Measurement of terminal complement complexes in rheumatoid arthritis</i> , Clin Exp Immunol. 1998 Sep;73(3):473-8. |
| O | Morgan BP, Walport MJ, <i>Complement deficiency and disease</i> , Immunol Today. 1991 Sep;12(9):301-6. |
| P | Morrison SL et al., <i>Chimeric human molecules: mouse antigen-binding domains with human constant region domains</i> , Proc Natl Acad Sci U S A. 1984 Nov;81(21):6851-5. |
| Q | Nakano S, Engel AG, <i>Myasthenia gravis: quantitative immunocytochemical analysis of inflammatory cells and detection of complement membrane attack complex at the end-plate in 30 patients</i> , Neurology. 1993 Jun;43(6):1167-72. |

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP §609;
 Draw line through citation if not in conformance and not considered. Include copy of this form with next
 communication to the patent applicants' attorney.

| | | | |
|--------------------------------------------------------------------------------------------------|--|--------------------------------|--------------------------|
| MODIFIED FORM PTO-1449 (REV. 6-89) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE | | ATTY DOCKET NO.: NMT-8440 | SERIAL NO. 10/716,929 |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use several sheets if necessary)</i> | | APPLICANT(S): Rekha Bansal | |
| | | FILING DATE: November 19, 2003 | GROUP: 1644 |

NON-PATENT LITERATURE DOCUMENTS (*Including Author, Title, Date, Pertinent Pages, Etc.*)

| | |
|---|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| A | Niculescu F, Rus H. <i>Complement activation and atherosclerosis</i> , Mol Immunol. 1999 Sep-Oct;36(13-14):949-55. |
| B | Pack P. et al., <i>Improved bivalent miniantibodies, with identical avidity as whole antibodies, produced by high cell density fermentation of Escherichia coli</i> , Biotechnology (NY). 1993 Nov;11(11):1271-7. |
| C | Pangburn, M.K., R.D. Schreiber, and H.J. Muller-Eberhard, <i>Formation of the initial C3 convertase of the alternative complement pathway. Acquisition of C3b-like activities by spontaneous hydrolysis of the putative thioester in native C3</i> . J Exp Med, 1981. 154 (3): p. 856-67. |
| D | Polhill, R.B., Jr., K.M. Pruitt, and R.B. Johnston, Jr., <i>Kinetic assessment of alternative complement pathway activity in a hemolytic system. I. Experimental and mathematical analyses</i> . J Immunol, 1978. 121 (1): p. 363-70. |
| F | Ravetch, J.V. and J.P. Kinet, <i>Fc receptors</i> . Annu Rev Immunol, 1991. 9 : p. 457-92. |
| F | Sandhu JS, <i>Protein engineering of antibodies</i> , Crit Rev Biotechnol. 1992;12(5-6):437-62. |
| G | Schafer Hansjorg, et al. <i>Deposition of the Terminal C5b-9 Complement Complex in infarcted areas of human Myocardium</i> , Journal of Immun. 1986; 137(6); p. 1945-1949 |
| H | Schmiedt, Walther et al., <i>Complement C6 Deficiency Protects Against Diet-Induced Atherosclerosis in Rabbits</i> , Arterioscler Thromb Vasc Biol. 1998;18:1790-1795. |
| I | Schulze, M. et al., <i>Glomerular C3c localization indicates ongoing immune deposit formation and complement activation in experimental glomerulonephritis</i> , Am J Pathol. 1993 Jan;142(1):179-87. |
| J | Seifert PS, et al. <i>Isolation and characterization of a complement-activating lipid extracted from human atherosclerosis lesions</i> , J Exp Med. 1990 Aug 1;172(2):547-57. |
| K | Seifert PS, et al., <i>Generation of Complement anaphylatoxins and C5b-9 by crystalline cholesterol oxidation derivatives depends on hydroxyl group number and position</i> , Mol Immunol. 1987 Dec;24(12):1303-8. |
| F | Seifert PS, et al. <i>The complement system in atherosclerosis</i> , Athrerosclerosis. 1988 Oct;73(2-3):91-104. |
| M | Singer II, et al., <i>Optimal humanization of 1B4, an anti-CD18 murine monoclonal antibody, is achieved by correct choice of human V-region framework sequences</i> , J Immunol. 1993 Apr 1;150(7):2844-57. |
| N | Stevens, John H., et al. <i>Effects of anti-C5a antibodies on the Adult Respiratory Distress Syndrome in Septic Primates</i> , 1986. 77: p. 1812-1816. |
| O | Tada, T. et al., <i>Membrane attack complex of complement and 20 kDa homologous restriction factor (CD59) in myocardial infarction</i> , Virchows Archiv, 1997. 430(4): p. 327-332. |
| P | Takabayashi T., et al., <i>A new biologic role for C3a and C3a desArg: regulation of TNF-alpha and IL-1 beta synthesis</i> , J Immunol. 1996 May 1;156(9):3455-60. |
| Q | Theil, Steffen et al., <i>Interaction of C1q abd Mannan-Binding Lectin (MBL) with C1r, c1s, MBL-Associated Serine Proteases 1 and 2, and the MBL-Associated Protein MA919</i> , J. Immunol 2000. 165:878-887. |

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP §609;
 Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the patent applicants' attorney.

| | | | |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------|
| MODIFIED FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (REV. 6-89) PATENT AND TRADEMARK OFFICE | | ATTY DOCKET NO.: NMT-8440 | SERIAL NO. 10/716,929 |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use several sheets if necessary)</i> | | APPLICANT(S): Rekha Bansal | |
| | | FILING DATE: November 19, 2003 | GROUP: 1644 |
| NON-PATENT LITERATURE DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) | | | |
| | A | Tomooka K., <i>Serum complement levels in patients with rheumatoid arthritis and vasculitis</i> , Fukuoka Igaku Zasshi. 1989 Oct;80(10):456-66. | |
| | B | Utley, J.R., <i>Pathophysiology of cardiopulmonary bypass: current issues</i> . J Card Surg, 1990. 5 (3): p. 177-89. | |
| | C | van de Winkel, J.G. and P.J. Capel, <i>Human IgG Fc receptor heterogeneity: molecular aspects and clinical implications</i> . Immunol Today, 1993. 14 (5): p. 215-21. | |
| | D | Vaughan, T.J., J.K. Osbourn, and P.R. Tempest, <i>Human antibodies by design</i> . Nat Biotechnol, 1998. 16 (6): p. 535-9. | |
| | E | Woodruff Trent M., et al., <i>A Potent Human C5a Receptor Antagonist Protects against disease Pathology in a Rat Model of Inflammatory Bowel Disease</i> , J. Immunol. 2003. 171:5514-5520 | |
| | F | Yasojima, K. et al., <i>Complement Components, but not Complement Inhibitors, Are Upregulated in Atherosclerotic Plaques</i> , Arterioscler. Thromb. Vasc. Biol. 2001;21:1214-1219. | |
| | G | Ames, R.S., et al., <i>Identification of a selective nonpeptide antagonist of the anaphylatoxin C3a receptor that demonstrates antiinflammatory activity in animal models</i> . J Immunol, 2001. 166 (10): p. 6341-8. | |
| | H | Hulett, M.D. and P.M. Hogarth, <i>Molecular basis of Fc receptor function</i> . Adv Immunol, 1994. 57 : p. 1-127. | |
| | L | Lin, Y.F., et al., <i>Cytokine production during hemodialysis: effects of dialytic membrane and complement activation</i> . Am J Nephrol, 1996. 16 (4): p. 293-9. | |
| | J | Liszewski, e.a.T.C.S.I.F.I., Third Edition, pp. 917-939. W. E. Paul (Ed.). Raven Press: New York. | |
| | P | | |
| | L | | |
| | M | | |
| | N | | |
| | O | | |
| | P | | |
| | Q | | |
| EXAMINER | | DATE CONSIDERED | |
| EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP §609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the patent applicants' attorney. | | | |